​
​

Traws Pharma (ONTX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Traws Pharma Revenue Highlights

Latest Revenue (Y)

$226.00B

Latest Revenue (Q)

$56.00K

Main Segment (Y)

Hanx Upfront Licence Payment

Main Geography (Y)

Hanx Upfront Licence Payment

Traws Pharma Revenue by Period

Traws Pharma Revenue by Year

DateRevenueChange
2023-12-31$226.00B99999900.00%
2022-12-31$226.00K-
2021-12-31$226.00K-2.16%
2020-12-31$231.00K-89.42%
2019-12-31$2.18M77.77%
2018-12-31$1.23M56.04%
2017-12-31$787.00K-85.81%
2016-12-31$5.55M-51.59%
2015-12-31$11.46M1332.00%
2014-12-31$800.00K-83.17%
2013-12-31$4.75M-89.71%
2012-12-31$46.19M3006.25%
2011-12-31$1.49M-

Traws Pharma generated $226.00B in revenue during NA 2023, up 99999900.00% compared to the previous quarter, and up 18403908.79% compared to the same period a year ago.

Traws Pharma Revenue by Quarter

DateRevenueChange
2024-03-31$56.00K-
2023-12-31$56.00K-1.75%
2023-09-30$57.00K-
2023-06-30$57.00K1.79%
2023-03-31$56.00K-
2022-12-31$56.00K-1.75%
2022-09-30$57.00K-
2022-06-30$57.00K1.79%
2022-03-31$56.00K-
2021-12-31$56.00K-1.75%
2021-09-30$57.00K-
2021-06-30$57.00K1.79%
2021-03-31$56.00K-1.75%
2020-12-31$57.00K-13.64%
2020-09-30$66.00K17.86%
2020-06-30$56.00K7.69%
2020-03-31$52.00K73.33%
2019-12-31$30.00K-52.38%
2019-09-30$63.00K-96.88%
2019-06-30$2.02M2873.53%
2019-03-31$68.00K15.25%
2018-12-31$59.00K-50.83%
2018-09-30$120.00K-75.26%
2018-06-30$485.00K-14.01%
2018-03-31$564.00K294.41%
2017-12-31$143.00K30.00%
2017-09-30$110.00K-66.05%
2017-06-30$324.00K54.29%
2017-03-31$210.00K21.39%
2016-12-31$173.00K-89.52%
2016-09-30$1.65M-26.56%
2016-06-30$2.25M52.51%
2016-03-31$1.47M-84.64%
2015-12-31$9.60M491.68%
2015-09-30$1.62M1218.70%
2015-06-30$123.00K7.89%
2015-03-31$114.00K-
2014-12-31$114.00K-
2014-09-30$114.00K-8.80%
2014-06-30$125.00K-72.04%
2014-03-31$447.00K-76.84%
2013-12-31$1.93M72.94%
2013-09-30$1.12M88.83%
2013-06-30$591.00K-47.04%
2013-03-31$1.12M-62.41%
2012-12-31$2.97M-93.06%
2012-09-30$42.80M19355.91%
2012-06-30$220.00K11.11%
2012-03-31$198.00K-

Traws Pharma generated $56.00K in revenue during Q1 2024, up 0.00% compared to the previous quarter, and up 100.00% compared to the same period a year ago.

Traws Pharma Revenue Breakdown

Traws Pharma Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 18
Symbio Amortization Of Upfront Payment$398.00K
Hanx Upfront Licence Payment$450.00K
Pint Upfront Licence Payment$319.00K
Supplies$61.00K

Traws Pharma's latest annual revenue breakdown by segment (product or service), as of Dec 18: Hanx Upfront Licence Payment (36.64%), Symbio Amortization Of Upfront Payment (32.41%), Pint Upfront Licence Payment (25.98%), and Supplies (4.97%).

Quarterly Revenue by Product

Product/ServiceSep 21Jun 21Mar 21Sep 20Jun 20Sep 19Jun 19Mar 19Sep 18Jun 18Mar 18
License$57.00K$57.00K$56.00K$56.00K$56.00K------
Supplies And Other---$10.00K$-4.00K------
Reimbursement Revenue-----$6.00K-----
Rigosertib-----$1.97M-----
Symbio Clinical Supplies------$1.00K$11.00K$6.00K$53.00K-
Symbio Amortization Of Upfront Payment------$56.00K$57.00K$114.00K$113.00K$114.00K
Hanx Upfront License Payment------$1.97M----
Pint Upfront Licence Payment---------$319.00K-
Hanx Upfront Licence Payment---------$450.00K-

Traws Pharma's latest quarterly revenue breakdown by segment (product or service), as of Sep 21: License (100.00%).

Traws Pharma Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 18
Hanx Upfront Licence Payment$450.00K
Symbio Amortization Of Upfront Payment$398.00K
Pint Upfront Licence Payment$319.00K
Supplies$61.00K

Traws Pharma's latest annual revenue breakdown by geography, as of Dec 18: Hanx Upfront Licence Payment (36.64%), Symbio Amortization Of Upfront Payment (32.41%), Pint Upfront Licence Payment (25.98%), and Supplies (4.97%).

Quarterly Revenue by Country

CountrySep 21Jun 21Mar 21Sep 20Jun 20Sep 19Jun 19Mar 19Sep 18Jun 18Mar 18
License$57.00K$57.00K$56.00K$56.00K$56.00K------
Supplies And Other---$10.00K$-4.00K------
Reimbursement Revenue-----$6.00K-----
Rigosertib-----$1.97M-----
Hanx Upfront License Payment------$1.97M----
Symbio Clinical Supplies------$1.00K$11.00K$6.00K$53.00K-
Symbio Amortization Of Upfront Payment------$56.00K$57.00K$114.00K$113.00K$114.00K
Pint Upfront Licence Payment---------$319.00K-
Hanx Upfront Licence Payment---------$450.00K-

Traws Pharma's latest quarterly revenue breakdown by geography, as of Sep 21: License (100.00%).

Traws Pharma Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ONTXTraws Pharma$226.00B$56.00K
JAGXJaguar Health$9.76M$3.07M
VBIVVBI Vaccines$8.68M$1.21M
TNXPTonix Pharmaceuticals$7.77M$2.82M
VXRTVaxart$7.38M$4.93M
PULMPulmatrix$7.30M$366.00K
OCGNOcugen$6.04M$1.14M
AEZSCOSCIENS Biopharma$4.58M$3.98K
CBIOGyre Therapeutics$794.00K-
PALIPalisade Bio$250.00K-
SONNSonnet BioTherapeutics$147.81K-
BPTHBio-Path--
MBRXMoleculin Biotech--
ADILAdial Pharmaceuticals--
GOVXGeoVax Labs-$300.68K
DFFNCervoMed--

ONTX Revenue FAQ

What is Traws Pharma’s yearly revenue?

Traws Pharma's yearly revenue for 2023 was $226B, representing an increase of 99999900.00% compared to 2022. The company's yearly revenue for 2022 was $226K, representing an increase of 0% compared to 2021. ONTX's yearly revenue for 2021 was $226K, representing a decrease of -2.16% compared to 2020.

What is Traws Pharma’s quarterly revenue?

Traws Pharma's quarterly revenue for Q1 2024 was $56K, a 0% increase from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $56K, a -1.75% decrease from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). ONTX's quarterly revenue for Q3 2023 was $57K, a 0% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).

What is Traws Pharma’s revenue growth rate?

Traws Pharma's revenue growth rate for the last 3 years (2021-2023) was 99999900.00%, and for the last 5 years (2019-2023) was 10352625.61%.

What are Traws Pharma’s revenue streams?

Traws Pharma's revenue streams in c 18 are Symbio Amortization Of Upfront Payment, Hanx Upfront Licence Payment, Pint Upfront Licence Payment, and Supplies. Symbio Amortization Of Upfront Payment generated $398K in revenue, accounting 32.41% of the company's total revenue Hanx Upfront Licence Payment generated $450K in revenue, accounting 36.64% of the company's total revenue Pint Upfront Licence Payment generated $319K in revenue, accounting 25.98% of the company's total revenue Supplies generated $61K in revenue, accounting 4.97% of the company's total revenue

What is Traws Pharma’s main source of revenue?

For the fiscal year ending Dec 18, the largest source of revenue of Traws Pharma was Hanx Upfront Licence Payment. This segment made a revenue of $450K, representing 36.64% of the company's total revenue.